MorphoSys AG (MOR),a biopharmaceutical company, Tuesday reported preliminary U.S. net products sales for its cancer drug Monjuvi for 2023 fourth quarter of $24.1 million.
For the year 2024, the company expects Monjuvi U.S. net product sales to be in the range of $80 million to $95 million, in line with its previous guidance.
Monjuvi was approved by the US FDA to treat diffuse large B-cell lymphoma in July 2020.
Fourth-quarter results are scheduled to be reported on March 13.
For comments and feedback: editorial@rttnews.com